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AbsTrACT
Adult-onset leukodystrophies and genetic 
leukoencephalopathies comprise a diverse group of 
neurodegenerative disorders of white matter with a 
wide age of onset and phenotypic spectrum. Patients 
with white matter abnormalities detected on MRi often 
present a diagnostic challenge to both general and 
specialist neurologists. Patients typically present with a 
progressive syndrome including various combinations 
of cognitive impairment, movement disorders, ataxia 
and upper motor neuron signs. There are a number 
of important and treatable acquired causes for this 
imaging and clinical presentation. There are also a very 
large number of genetic causes which due to their 
relative rarity and sometimes variable and overlapping 
presentations can be difficult to diagnose. in this review, 
we provide a structured approach to the diagnosis 
of inherited disorders of white matter in adults. we 
describe clinical and radiological clues to aid diagnosis, 
and we present an overview of both common and rare 
genetic white matter disorders. we provide advice on 
testing for acquired causes, on excluding small vessel 
disease mimics, and detailed advice on metabolic and 
genetic testing available to the practising neurologist. 
Common genetic leukoencephalopathies discussed in 
detail include CSF1R, AARS2, cerebral arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASiL), 
and mitochondrial and metabolic disorders.
INTroduCTIoN
Adult patients with extensive white matter hyper-
intensities on MRI present the neurologist with a 
complex diagnostic task. There are a wide variety 
of disorders that can lead to these imaging appear-
ances, including inflammatory, infective and 
malignant causes, as well as extensive small vessel 
disease. Often the most difficult patients to diag-
nose however are those with presumed genetic 
conditions, including the classical leukodystro-
phies, where the primary pathology is based in 
the myelin, or the genetic leukoencephalopathies, 
where the pathology is mainly neuronal or systemic. 
Patients may present with a wide spectrum of clin-
ical features, including cognitive and neuropsy-
chiatric changes, movement disorders, spasticity 
and seizures. The diversity of genetic aetiologies 
combined with the often-overlapping clinical and 
radiological phenotypes can make definitive diag-
nosis challenging.
In 2014 we set out a practical approach to navi-
gate through the maze.1 However, even in the space 
of 5 years, there has been a substantial increase in 
the number of implicated genes. Improved pheno-
type–genotype correlation and increased access to 
advanced sequencing technologies have therefore 
changed our diagnostic approach.
This new review provides an opportunity to 
update and refine our practical approach for the 
diagnosis of genetic leukoencephalopathies in 
the era of whole genome sequencing. We would 
strongly recommend that it be read with the 
previous paper to avoid any repetition. As before, 
we emphasise the need to exclude as far as possible 
any acquired disorder, emphasise facets of the rela-
tively commoner classical leukodystrophies/leuko-
encephalopathies, then highlight newer emerging 
diseases. Clinical/MRI features which point towards 
certain conditions are described. We end with an 
algorithm that we have found useful and describe 
our own experience.
For clarity, we are describing an approach where 
the symptoms have begun after the age of 16 and 
the MRI shows widespread cranial white matter 
change on standard (T2, fluid-attenuated inversion 
recovery (FLAIR)) sequences.
Excluding common acquired 
leukoencephalopathies
As emphasised previously it is imperative that treat-
able and acquired causes of white matter disease 
are ruled out as far as possible, before the patient 
is referred for investigation of a genetic leukodys-
trophy. As a minimum, all patients should undergo 
infective screening, including testing for HIV, syph-
ilis, hepatitis B/C and tuberculosis. Patients with 
a history of immunosuppression should be tested 
for progressive multifocal leukoencephalopathy by 
cerebrospinal fluid (CSF) examination for the pres-
ence of JC virus. A high index of suspicion should 
remain for neoplasia, including primary central 
nervous system (CNS) lymphoma and gliomatosis 
cerebri. A careful history will reveal if the patient 
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Figure 1 Axial T2-weighted MRi of radiotherapy changes (A), as well 
as axial FLAiR MRi of cerebral Systemic Lupus eythematosus (SLe) (B) 
and PReS (C) demonstrating symmetrical and confluent periventricular 
and subcortical white matter signal hyperintensity (wMH). Axial non-
contrast CT demonstrating subcortical volume loss, punctate calcification 
and confluent hypodensity adjacent to the frontal horns of the lateral 
ventricles (D). Axial B1000 Dwi and FLAiR MRi acquisitions showing Dwi 
avid punctate lesions (e) as well as confluent periventricular hyperintense 
signal changes (F) in CSF1R leukodystrophy. MRi sagittal T1w acquisition 
showing diffuse thinning of the corpus callosum (G), as well as axial 
T1w (H) and FLAiR (i) sequences demonstrating confluent rarefaction of 
the subcortical and periventricular white matter adjacent to the frontal 
horns and ventricular trigones of the lateral ventricles in vwM disease. 
FLAiR, fluid-attenuated inversion recovery; PReS, posterior reversible 
leukoencephalopathy syndrome; T1w, T1-weighted; vwM, vanishing white 
matter.
(figure 1A) (in particular 5-fluorouracil and methotrexate) 
and recreational drugs like heroin or methanol, which can all 
lead to confluent, symmetrical leukoencephalopathy. Treatable 
inflammatory disorders like systemic lupus erythematosus must 
be considered (figure 1B,C). Posterior reversible leukoenceph-
alopathy syndrome causes a dramatic leukoencephalopathy 
often with infarcts and microhaemorrhages (figure 1D), which 
improves over time. Further guidance on the initial work-up of 
these patients can be found in round 1 investigations (online 
supplementary table 1 in: Ahmed et al,1 Journal of Neurology, 
Neurosurgery, and Psychiatry).
Features suggestive of an acquired disorder include rapid 
onset, steroid responsiveness, systemic features, MRI gado-
linium enhancement and cervical cord involvement—although 
of course there are exceptions as discussed below.
severe small vessel disease or genetic leukoencephalopathy?
A large number of patients referred for investigation will not 
be diagnosed with a genetic leukodystrophy, but instead will 
be diagnosed with severe acquired small vessel disease. These 
patients are more likely to present at an older age, have signifi-
cant cardiovascular risk factors, and clinically are often asymp-
tomatic or experience slow, indolent decline. They lack a clear 
family history to suggest a genetic origin. Imaging is likely to 
show increased T2/FLAIR signal in the periventricular and cere-
bral white matter, the basal ganglia, pons and cerebellum with 
chronic lacunes and cerebral microbleeds.2 In contradistinc-
tion to many inflammatory disorders such as multiple sclerosis, 
cervical cord imaging will be normal. In older patients (eg, >60 
years), extensive genetic testing is unlikely to reveal a cause.3 
However, in patients with this imaging appearance at a younger 
age, consideration should be given to the genetic forms of small 
vessel disease (eg, cerebral arteriopathy with subcortical infarcts 
and leukoencephalopathy (CADASIL), COL4A1), which are 
discussed below.
Clinical and radiological pattern recognition
Many adult-onset leukoencephalopathies present in the same 
way, with a variable degree of cognitive decline, spasticity, 
apraxia and ataxia. This presentation is non-specific, and in 
these cases a non-biased approach using knowledge of the most 
frequent syndromes and next-generation sequencing technolo-
gies is the most efficient route to a diagnosis. However, many 
of the syndromes described below have particular clues to diag-
nosis which may be found in a careful history and neurological 
examination. The mode of inheritance is important and can 
limit the number of conditions to consider (table 1); however, 
the most common inheritance pattern in adults is sporadic. 
This may suggest an autosomal recessive mode of inheritance 
in a small family, reduced penetrance in an autosomal dominant 
condition or even a censored family history. The ethnicity of 
the patient and geographical region of origin are relevant as the 
frequency of each disorder can vary substantially in different 
regions.
>The most helpful and discriminating symptoms and signs 
are described in table 2. These include the importance of noting 
endocrine abnormalities such as premature ovarian failure 
(POF) (vanishing white matter (VWM) disease, AARS2) or 
hypogonadotrophic hypogonadism (Gordon Holmes syndrome, 
POLR3-related disorders). Movement disorders such as promi-
nent parkinsonism or chorea are important, as are the presence 
of early autonomic (LMNB1) or urinary symptoms (adult poly-
glucosan body disease). Peripheral demyelinating neuropathy 
may suggest metachromatic leukodystrophy (MLD), and adrenal 
failure is highly suggestive of adrenoleukodystrophy (ALD).
Similarly to the clinical presentations, the radiological 
appearance of genetic leukoencephalopathies can be non-spe-
cific, but there are important features to note. Deep white 
matter diffusion abnormalities have been well described in 
CSF1R and AARS2, in addition to prominent involvement of the 
corpus callosum. A patchy leukoencephalopathy with lacunes, 
microhaemorrhages and anterior temporal lobe involvement is 
suggestive of a vascular disorder such as CADASIL or cathepsin 
A-related arteriopathy with strokes and leukoencephalopathy 
(CARASAL). Hypomyelination is an important sign to note, 
as there are only a small number of genetic diseases known to 
cause this radiological appearance. Useful radiological signs can 
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Table 1 Leukoencephalopathies known to present in adulthood
disorder Inheritance Investigation Gene
Adult-onset leukodystrophies
Inherited disorders of metabolism associated with abnormal biochemical tests
  X linked adrenoleukodystrophy X linked Very long chain fatty acids ABCD1
  Krabbe disease AR WCE
(galactocerebrosidase)
GALC, PSAP
  Metachromatic leukodystrophy AR WCE (arylsulfatase A)
Urine sulfatides
ARSA
  Cerebrotendinous xanthomatosis AR Serum cholestenol, urine bile alcohols CYP27A1
  Methylenetetrahydrofolate reductase deficiency AR Plasma amino acid profile MTHFR
  Homocystinuria AR Plasma amino acid profile CBS




disorder Acronym Inheritance Gene
Genetic leukoencephalopathies
  Hereditary diffuse leukoencephalopathy with axonal spheroids and pigmented glia HDLS AD CSF1R
  Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy CADASIL AD NOTCH3
  Cerebral autosomal recessive cerebral arteriopathy with subcortical infarcts and leukoencephalopathy CARASIL AR HTRA1
  Cathepsin A-related arteriopathy with strokes and leukoencephalopathy CARASAL AD CTSA
  Cerebral leukodystrophy with retinal vasculopathy AD TREX1
  Small vessel disease with ocular abnormalities AD COL4A1
  Alexander disease AD GFAP
  Adult-onset autosomal dominant leukodystrophy ADLD AD LMNB1 duplication
  AARS2-related leukodystrophy AARS2-L AR AARS2
  Vanishing white matter disease VWM AR EIF2B1-5
  Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation LBSL AR DARS2
  Mitochondrial neurogastrointestinal encephalopathy MNGIE AR TYMP
  Pelizaeus-Merzbacher disease PMD X linked dominant PLP1
  Pelizaeus-Merzbacher-like disease PMLD AR GJC2
  Adult polyglucosan body disease APBD AR GBE
  Hypomyelinating leukodystrophy with atrophy of the basal ganglia and cerebellum H-ABC AD TUBB4A
  Leukoencephalopathy with ataxia LKPAT AR CLCN2
  4H syndrome AR POLR3A/POLR3B
  Labrune syndrome AR SNORD118
  Gordon Holmes syndrome AR RNF216
  Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy PLOSL AR TREM2
TYROBP
AD, Autosomal Dominant; AR, Autosomal recessive; WCE, White Cell Enzymes.
Metabolic leukodystrophies
After excluding common acquired leukoencephalopathies, 
the first priority should be to identify patients with an inher-
ited metabolic disorder. A small number of tests will detect 
the diseases that present in adulthood. Recommended testing 
includes a very long chain fatty acid (VLCFA) profile in men 
(ALD), specific white cell enzyme activities (Krabbe disease, 
MLD), raised serum cholestanol/urinary bile alcohols (cere-
brotendinous xanthomatosis (CTX)) and plasma amino acids 
(methylenetetrahydrofolate reductase (MTHFR) deficiency and 
homocystinuria) (table 1).
X linked ALd
Adult-onset ALD is a rare X linked metabolic disorder of peroxi-
somal fatty acid beta-oxidation which results in the accumula-
tion of VLCFA in plasma and tissues, including white matter and 
the adrenal cortex.4
ALD is associated with three main phenotypes, including 
Addison-only disease, adrenomyeloneuropathy (AMN) and 
cerebral ALD (CALD). Addison-only presents most commonly 
by age 8 years, and although it begins without evidence of 
neurological abnormality some degree of disability (most 
commonly AMN) usually develops later. Indeed, virtually all 
patients with ALD who reach adulthood develop AMN, usually 
between 20 and 30 years of age. AMN is a non-inflammatory 
distal axonopathy, and is characterised by progressive spastic 
paraparesis, sensory ataxia, sphincter dysfunction, impotence 
and pain. CALD usually only affects men and presents with 
rapidly progressive inflammatory demyelination in the brain, 
leading to rapid cognitive and neurological decline, dementia, 
ataxia, seizures and death.
MRI is always abnormal in neurologically symptomatic men 
with cerebral disease. Early changes include T2/FLAIR hyper-
intensities in the parieto-occipital regions and splenium of the 
corpus callosum. A minority of patients will demonstrate signal 
abnormalities predominantly in the frontal lobes and genu of 
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Table 2 Clinical features that can be associated with specific 
leukodystrophies
Clinical characteristics of specific leukodystrophies
Premature ovarian failure VWM.
Galactosaemia.
AARS2-L.
Hypogonadotrophic hypogonadism Gordon Holmes syndrome.
4H syndrome.
Parkinsonism HDLS.
Chorea Gordon Holmes syndrome.
Palatal myoclonus Alexander disease.










Dental abnormalities 4H syndrome.
Tendon xanthomata CTX.
Early urinary frequency APBD.
Early autonomic features ADLD.
Early prominent ataxia CTX.
Gordon Holmes syndrome.
LKPAT.
Migraine with aura CADASIL.
Cataracts CTX mtDNA mutations.
Occasional rapid progression (<1 year) ALD.
Krabbe disease.
ADLD, adult-onset, autosomal dominant leukodystrophy; ALD, 
adrenoleukodystrophy; APBD, adult polyglucosan body disease; CADASIL, 
cerebral arteriopathy with subcortical infarcts and leukoencephalopathy; CTX, 
cerebrotendinous xanthomatosis; HDLS, hereditary diffuse leukoencephalopathy 
with spheroids; LBSL, leukoencephalopathy with brainstem and spinal cord 
involvement with elevated lactate; LKPAT, leukoencephalopathy with ataxia; 
MLD, metachromatic leukodystrophy; PMD, Pelizaeus-Merzbacher disease; VWM, 
vanishing white matter.
Table 3 Imaging features associated with specific leukodystrophies
Imaging characteristics of specific leukodystrophies
Frontal predominance Alexander disease.






Anterior temporal lobe signal abnormality CADASIL.
CARASIL.
CARASAL.
Deep white matter diffusion dots HDLS.
AARS2-L.
Corpus callosum involvement HDLS.
AARS2-L.
HSP genes (SPG11, SPG15, Fa2H).
’Tadpole brainstem’ (atrophy of the cervical 
cord and medulla with preserved pons)
Alexander disease.
Dentate nucleus signal change/cysts CTX.








Periventricular microcalcifications (visible on 
CT)
HDLS.
Extensive calcifications and cysts Labrune syndrome.
Bone cysts on X-ray PLOSL.
ALD, adrenoleukodystrophy; APBD, adult polyglucosan body disease; CADASIL, 
cerebral arteriopathy with subcortical infarcts and leukoencephalopathy; 
CARASAL, cathepsin A-related arteriopathy with strokes and leukoencephalopathy; 
CARASIL, cerebral autosomal recessive arteriopathy with subcortical infarcts 
and leukoencephalopathy; CTX, cerebrotendinous xanthomatosis; H-ABC, 
Hypomyelination with atrophy of the basal ganglia and cerebellum; HDLS, 
hereditary diffuse leukoencephalopathy with spheroids; HSP, Hereditary Spastic 
Paraplegia; LBSL, leukoencephalopathy with brainstem and spinal cord involvement 
with elevated lactate; LKPAT, leukoencephalopathy with ataxia; PLOSL, polycystic 
lipomembranous osteodysplasia with sclerosing leukoencephalopathy; PMD, 
Pelizaeus-Merzbacher disease; PMLD, Pelizaeus-Merzbacher-like disorder.
Elevated levels of VLCFAs in the blood are suggestive of 
a peroxisomal disorder, and the diagnosis of ALD can be 
confirmed by sequencing of the ABCD1 gene. Early diagnosis 
and family screening are essential to reduce the risk of untreated 
hypoadrenalism, and to identify early those patients who may 
benefit from haematopoietic stem cell transplantation (HSCT).6
Krabbe disease
Krabbe disease is a rare autosomal recessive disorder caused 
by loss of function mutations in GALC, leading to deficiency 
of galactocerebrosidase, a lysosomal enzyme responsible for the 
degradation of galactocerebroside to ceramide and galactose. In 
Krabbe disease, galactocerebroside accumulates in the peripheral 
and central nervous system producing cerebral atrophy, loss of 
myelin, gliosis and globoid cells.7
There are three forms of Krabbe disease: infantile, juvenile 
and adult. The infantile form is the most severe and usually pres-
ents between 3 and 6 months of age. After a normal neonatal 
period, those affected develop a rapidly progressive course 
involving irritability, hyperaesthesia, visual and hearing loss, 
severe cognitive and motor deterioration, and seizures. This 
group rarely survives beyond 2 years. Nerve conduction studies 
show a demyelinating peripheral neuropathy and CSF analysis 
may reveal increased total protein concentration.8
Juvenile and adult (late) forms of the disease have a milder, 
more varied phenotype, a slower rate of progression and a 
significantly longer lifespan (although we have observed a 
rapid deterioration over a year in one case). Typical features 
include spasticity, dementia, ataxia, peripheral neuropathy and 
visual loss. The T2/FLAIR signal abnormality in Krabbe disease 
predominantly affects the corticospinal tracts, from the cortex, 
through the corona radiata internal capsules and cerebral pedun-
cles.9 The optic radiations are frequently involved,9 and intracra-
nial calcifications have been reported, but may only be apparent 
on CT imaging.10
The diagnosis of Krabbe disease can be made by assay of galac-
tosylceramidase activity via white cell enzyme testing.
Metachromatic leukodystrophy
MLD is an autosomal recessive disorder caused mainly by defi-
cient activity of arylsulfatase A (ARSA). ARSA is responsible 
for the desulfation of cerebroside sulfate, a major glycolipid of 
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of cerebroside sulfate in the CNS and peripheral nerves (as well 
as the kidneys and other visceral organs). The result is central 
and peripheral demyelination.11
In almost all cases, recessive mutations in the ARSA gene are 
responsible, although very rarely, MLD can be caused by muta-
tions in the PSAP gene.12 Three major subtypes exist—late infan-
tile (age 6 months to 2 years), juvenile (age 3–16 years) and adult 
(age >16). Peripheral neuropathy occurs in all forms and gall-
bladder involvement (hyperplastic polyps) is also common. Late 
infantile onset is associated with poor prognosis (death typically 
occurs within 5–6 years) and manifests as regression of motor 
skills, gait abnormalities, seizures, ataxia, hypotonia, extensor 
plantars and optic atrophy. Juvenile disease presents similarly 
but is more heterogeneous. Progression is slower, and these chil-
dren may survive until early adulthood. Adult onset is usually 
heralded by dementia, behavioural difficulties, and in a minority 
with psychosis.13
Nerve conduction studies show marked slowing. Brain MRI 
reveals symmetric periventricular white matter lesions and 
cortical atrophy, often with a tigroid or stripe pattern, caused 
by the appearance of the spared perivascular white matter.14 
Diagnosis is established by demonstrating deficient ARSA 
activity in leucocytes (white cell enzyme testing) or cultured 
skin fibroblasts. Clinicians should be aware of the pseudodefi-
ciency state, in which ARSA activity levels are low, but do not 
cause disease. In pseudodeficiency, the activity level is typically 
5%–20% of controls.15 In affected individuals with MLD, 
urine sulfatide excretion is increased, generally tenfold to a 
hundred-fold greater than controls. Urine sulfatide excretion 
may therefore be used to differentiate pseudodeficiency from 
deficiency. However, the assay for urine sulfatide excretion is 
not currently routinely available in the UK and, as testing for 
the pseudodeficiency variants can be done rapidly, this is the 
usual first-line test.
No curative treatment is currently available, but HSCT has 
slowed disease progression in some patients.16 Other promising 
novel treatments include gene therapy and enzyme replacement.17
Cerebrotendinous xanthomatosis
CTX is an autosomal recessive disorder of bile acid synthesis 
caused by mutation of the cytochrome P450 gene CYP27A1, 
resulting in the production of defective sterol 27-hydroxylase. 
Consequently, CTX is associated with high levels of cholestanol 
in plasma and its accumulation in tissue. This gives rise to hall-
mark clinical manifestations of chronic diarrhoea, bilateral cata-
racts, tendon xanthomas or tendon thickening, and neurological 
dysfunction.18
Typical neurological manifestations can include intellec-
tual disability, autism, behavioural and psychiatric problems, 
dementia, ataxia and epilepsy. MRI studies show cerebral and 
cerebellar atrophy, extensive white mater lesions of the spinal 
cord, and bilateral T2/FLAIR hyperintensity of the dentate 
nuclei and surrounding white matter.
Cholestanol concentrations are increased in plasma, brain, 
xanthomas and bile. Increased quantities of bile alcohols are 
useful as a secondary diagnostic test. CSF levels of cholestanol, 
cholesterol, apolipoprotein B, apolipoprotein A1 and albumin 
are increased.18
Treatment is with chenodeoxycholic acid (a cholesterol 7α-hy-
droxylase enzyme inhibitor), which is effective in improving 
biochemical findings, and in those without advanced disease may 
improve or stabilise neurological features.19
MTHFr deficiency
Autosomal recessive mutations in the MTHFR gene cause a 
spectrum of symptoms, with onset ranging from childhood to 
adulthood. Biochemically, there are elevated plasma homocys-
teine, homocystinuria and low methionine levels. Patients may 
develop seizures, cognitive decline, recurrent thrombotic stroke 
and leukoencephalopathy. The neurological signs may improve 
with treatment, the mainstay of which is folic acid and betaine 
supplementation.20
Genetic leukoencephalopathies
Since our previous review, a number of conditions have gained in 
prominence or have been newly described. They are diagnosed 
genetically, although as shown in tables 2 and 3 there can be 
typical diagnostic features to focus the genetic analysis.
CSF1R
Mutations in the CSF1R (colony stimulating factor-1 receptor) 
gene are known to cause an adult-onset leukodystrophy 
termed hereditary diffuse leukoencephalopathy with spher-
oids (HDLS).21 This condition has been shown to be one of the 
most common causes of adult-onset leukodystrophy, accounting 
for approximately 10% of cases.22 First described in a large 
Swedish kindred,23 this is an autosomal dominant disorder in 
which affected members develop a clinical course characterised 
by dementia, psychiatric changes and motor decline. The age 
of onset is variable, even within families, but typically patients 
develop symptoms in their 40s (range 18–78 years). The pene-
trance of the disorder is not known, but is likely to be high. 
Because of incomplete penetrance (and the possibility of de novo 
mutations), some affected patients will not have a family history 
and may appear to have a sporadic disorder.
The condition is found worldwide and has a well-described 
clinical phenotype. Prominent symptoms include parkin-
sonism,24 which is usually not levodopa-responsive, and upper 
motor neuron signs such as spasticity and ataxia. A recent large 
review found the mean disease duration to be 6.8 years from 
symptom onset to death.25
Pathologically the disease is characterised by the presence of 
astrogliosis with myelin and axonal loss and frequent axonal 
spheroids in the cerebral white matter. The spheroids are visible 
with H&E staining, but also stain positive for neurofilaments, 
p62, amyloid precursor protein APP and β amyloid. There are 
typically pigmented microglia present which are autofluorescent 
and stain positive for CD68. The pathological appearance of this 
disorder is relatively specific and lends the disease its name. Prior 
to the identification of the responsible gene, the diagnosis of 
HDLS could only be confirmed pathologically.
The MRI appearance of HDLS is consistent, with typical 
features including confluent, largely symmetric T2 hyperin-
tense/T1 hypointense signal abnormality in the frontoparietal 
and periventricular white matter, which spares the U-fibres, and 
involves the pyramidal tracts and corpus callosum.26 Punctate 
areas of restricted diffusion may be present (termed deep white 
matter diffusion dots) and their appearance may even mimic 
CNS vasculitis.22 Calcifications may be present, particularly in 
the periventricular white matter adjacent to the frontal horns 
(figure 1D–F).
It was shown in 2011 that HDLS is largely caused by muta-
tions in the CSF1R gene.21 27 Almost all mutations are found 
in the tyrosine kinase domain of the CSF1R protein and the 
majority of mutations are missense. A small number of splice 
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AARS2
Mutations in AARS2 (alanyl-transfer (t)RNA synthetase 2) are 
emerging as a rare cause of leukodystrophy with similar clinical, 
imaging and radiological phenotype to CSF1R mutations.28 29 
This is an autosomal recessive disorder, but frequently appears 
sporadic, with a younger age of onset than CSF1R (mean age 29 
years, range 15–44 years). However the initial symptoms are very 
similar, with psychiatric changes and cognitive decline, parkin-
sonism, pyramidal signs, ataxia and seizures. Almost all female 
cases have experienced POF, although no endocrine or repro-
ductive abnormalities are found in men. MRI features include 
largely symmetric and confluent T2 hyperintense/T1 hypointense 
white matter signal change in the frontoparietal white matter, 
corpus callosum and pyramidal tracts. There are punctate areas 
of restricted diffusion on diffusion weighted imaging (DWI) 
often running parallel to the ventricles. A distinguishing feature 
from CSF1R is that the white matter signal suppresses on FLAIR 
imaging, indicating a degree of rarefaction.26
The clinical picture over time remains similar to CSF1R, with 
early cognitive symptoms followed by severe and rapid motor 
decline. Most patients are fully dependent within 5 years of 
symptom onset. In one case, pathological features of HDLS were 
found on brain biopsy, with axon and myelin loss and frequent 
axonal spheroids containing neurofilament, p62, APP and β 
amyloid. Pigmented microglia were also seen, and the patho-
logical features were felt to be indistinguishable from HDLS. 
In another case, no pathological abnormalities were found in 
a brain biopsy,29 30 and further pathological descriptions are 
required.
AARS2 encodes a t-RNA synthetase responsible for correctly 
loading alanine onto tRNA-ala for the translation of mitochon-
drial proteins. Most commonly patients will have compound 
heterozygous AARS2 mutations, although homozygous cases 
have also been reported. Loss of function mutations (frameshift, 
nonsense, splice site) are the most common, but there are some 
pathogenic missense mutations, including the recurrent R199C 
mutation. Mutations in this class of genes (tRNA synthetases) are 
increasingly implicated in a diverse range of neurological disor-
ders.31 32
VWM disease
VWM disease is an autosomal recessive disorder character-
ised by progressive neurological impairment and the cystic 
degeneration of white matter that is visible on MRI. It most 
commonly presents in childhood, but many adult-onset cases 
have been reported. The most frequent presenting features 
include ataxia, spasticity, seizures and cognitive decline. Often 
patients will experience episodes of severe neurological deteri-
oration after a minor insult, such as a head trauma, an infection 
or even emotional distress.33 An additional feature in women 
with VWM is POF; hence, VWM is sometimes referred to as 
ovarioleukodystrophy.
In one study of adult-onset VWM, the mean age of onset was 
found to be 31 years, with clinical features including neuro-
logical and psychiatric presentations. Frequent MRI features 
included cerebral and cerebellar atrophy and cavitating leuko-
encephalopathy with involvement of the corpus callosum.34 The 
characteristic feature is that the periventricular white matter 
takes on the same signal intensity as the CSF on T2-weighted 
and FLAIR imaging (figure 1G–I). VWM is caused by homozy-
gous and compound heterozygous mutations in any of the five 
genes that encode the subunits of the translation initiation factor 
EIF2B (EIF2B1–EIF2B5).35
Vascular leukoencephalopathies
A number of different genes come under the umbrella term 
of vascular leukoencephalopathies, including NOTCH3 
(CADASIL), HTRA1 (cerebral autosomal recessive arteriopathy 
with subcortical infarcts and leukoencephalopathy (CARASIL)), 
CTSA (CARASAL), COL4A1 and TREX1.
Cerebral arteriopathy with subcortical infarcts and 
leukoencephalopathy
CADASIL is caused by heterozygous mutations in the 
NOTCH3 gene. The condition is autosomal dominant and 
is characterised by recurrent stroke at a young age, cognitive 
decline, migraine with aura and depression.36 The mean age of 
first stroke is 46 years and typically the events are subcortical, 
ischaemic lacunes. Reversible episodes of encephalopathy may 
also occur. On brain MRI, the first abnormality detected is 
often white matter signal abnormality in the temporal poles. 
Over time the burden of white matter lesions increases, with 
the periventricular, frontoparietal and external capsular white 
matter most affected.37 There are frequently dilated perivas-
cular spaces and subcortical lacunes. Microhaemorrhages may 
be detected on gradient echo imaging (figure 2A–C). The diag-
nosis is supported by the finding of granular osmiophilic mate-
rial in small arterioles by electron microscopic examination of 
tissue, usually a skin biopsy. Pathogenic NOTCH3 mutations 
lead to the gain or loss of a cysteine residue in one of the 
epidermal growth factor-like repeat (EGFr) domains of the 
NOTCH3 protein. These EGFr domains normally contain six 
cysteine residues, and any alteration in this number has been 
shown to lead to NOTCH3 aggregation. NOTCH3 mutations 
are not fully penetrant, but it has been shown that cysteine 
altering mutations affecting the first six EGFr domains are the 
most penetrant and are associated with the highest burden of 
white matter disease.38
Cerebral autosomal recessive arteriopathy with subcortical 
infarcts and leukoencephalopathy
This autosomal recessive disorder is caused by biallelic mutations 
in the HTRA1 gene. CARASIL was first identified and is most 
common in Japan, but cases in Europe and South America have 
also been identified.39 40 Clinically it is characterised by dementia, 
parkinsonism, upper motor neuron signs, and extraneurological 
features including alopecia and back pain with spondylosis defor-
mans. Acute strokes are common and the typical age of onset is 
the teenage years to 20s. MRI appearance is similar to CADASIL 
(above), with spondylosis deformans potentially visible on spinal 
imaging.41
Recently, it has been proposed that heterozygous HTRA1 
mutations can also lead to autosomal dominant severe small 
vessel disease. In one study these patients were termed ‘mani-
festing heterozygotes with CARASIL’ and were described with a 
similar but less severe phenotype to recessive mutations.42 Spon-
dylosis was found in all manifesting heterozygotes. However, 
another recent study found that the phenotype of heterozy-
gous HTRA1 mutations was different from both CADASIL and 
CARASIL, and no extraneurological features were observed, 
although the imaging appearance was similar.43
Cathepsin A-related arteriopathy with strokes and 
leukoencephalopathy
This very recently described entity due to heterozygous muta-
tions in the CTSA gene is named cathepsin A-related arteriopathy 
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Figure 2 Axial FLAiR MRi sequences demonstrating confluent signal 
hyperintensity involving the external capsules, posterior limb of the 
internal capsules, peritrigonal white matter and splenium of the corpus 
callosum (A), as well as of the subcortical white matter of the temporal 
poles and central pons (B) in CADASiL. Minimal intensity projection 
from a susceptibility weighted imaging acquisition MRi demonstrating 
multiple punctate foci of paramagnetic susceptibility limited within the 
thalamus, left putamen and subcortical white matter of the left occipital 
lobe (C), in keeping with multiple microhaemorrhages in CADASiL. Axial 
T2w MRi sequences demonstrating signal hyperintensity within the 
trigeminal fascicles and cerebellar white matter (D), as well as within 
the pyramids, decussation of the medial lemnisci and inferior cerebellar 
peduncles at the level of the medulla oblongata (e) in LBSL. A sagittal 
T2w sequence of the upper spinal cord in the same patient demonstrates 
contiguous longitudinally extensive signal hyperintensity of the dorsal 
columns and lateral cortical spinal tracts (F). Axial T2w (G) and T1w (H) 
MRi sequences in a patient with Pelizaeus-Merzbacher disease illustrating 
the confluent diffuse T2w hyperintense signal within the white matter of 
the cerebrum, appearing unremarkable on the T1w sequences, suggestive 
of hypomyelination. Axial T2w sequences demonstrating confluent 
hyperintense signal change within the pons, middle cerebellar peduncles 
and dentate nuclei in a patient with a CNCL2 leukodystrophy (i). CADASiL, 
cerebral arteriopathy with subcortical infarcts and leukoencephalopathy; 
FLAiR, fluid-attenuated inversion recovery; T1w, T1-weighted; LBSL, 
leukoencephalopathy with brainstem and spinal cord involvement with 
elevated lactate; T2w, T2-weighted.
report described two Dutch families, distantly related, in whom 
members were affected by a severe leukoencephalopathy, accom-
panied often by ischaemic or haemorrhagic stroke, therapy-resis-
tant hypertension and later cognitive decline.44 The MRI pattern 
was very similar to CADASIL. Since the initial report, another 
case has been described from the UK with identical imaging and 
a similar phenotype, although with additional prominent brain-
stem features reported.3 45 To date, all patients described have 
carried the same R325C mutation in CTSA. It is unclear whether 
this is the only mutation in CTSA which is causal for CARASAL 
or whether further mutations will be identified.
COL4A1 and TREX1
Both COL4A1 and TREX1 are associated with leukoencephalop-
athies in which ocular or retinal abnormalities may be present. 
COL4A1 is characterised by diffuse leukoencephalopathy, often 
with dilated perivascular spaces and microhaemorrhages, and 
retinal abnormalities including arteriolar tortuosity or retinal 
haemorrhage.46 It is an autosomal dominant disorder and shows 
incomplete penetrance. Additional CNS features include intra-
cerebral haemorrhage, calcifications and cerebellar atrophy. 
Ocular abnormalities are not exclusively confined to the retina in 
COL4A1 with anterior segment dysgenesis, congenital cataract 
and nystagmus all reported.47 A second form of leukoenceph-
alopathy with retinal vasculopathy is caused by heterozygous 
frameshift mutations in the c-terminus of the TREX1 gene.48 In 
addition to the microvascular disease of the retina which can lead 
to visual loss, Raynaud’s phenomenon and migraine are both 
frequently found.49 A phenotype of TREX1 mutations called 
hereditary endotheliopathy with retinopathy, nephropathy and 
stroke may present with progressive, contrast-enhancing lesions 
with surrounding oedema, which may be mistaken for tumours.50 
Calcifications are found in more than 50% of patients.51
Mitochondrial dNA mutations
Mitochondrial DNA mutations are a rare cause of adult-onset 
leukoencephalopathy. Typically patients will present with a 
multisystem disorder, often including short stature, migraine, 
sensorineural deafness, cardiac defects and exercise intoler-
ance. There is often involvement of the deep grey structures on 
imaging, such as the basal ganglia and thalamus, but symmetric 
and confluent white matter abnormalities can occur.52 Stroke-
like episodes or cortical blindness would point to mitochondrial 
encephalopathy with lactic acidosis and stroke-like episodes 
(m.3243A>G); myoclonus, seizures and ataxia are sugges-
tive of mitochondrial encephalopathy with ragged red fibres 
(m.8344A>G). Periventricular signal abnormalities have been 
reported in Leber’s hereditary optic neuropathy, but only as a 
minor feature.53 Common mitochondrial point mutations can be 
readily screened in blood, but if these are negative and a suspicion 
of mitochondrial disease remains, next-generation sequencing of 
the complete mitochondrial genome from the muscle may be 
necessary. Clinicians should be aware that exome sequencing 
and panel-based sequencing typically target only nuclear genes, 
that is, not mitochondrial DNA. There are methods to extract 
mitochondrial DNA sequence from exome data, but this is not 
commonly done.
Nuclear encoded mitochondrial genes
There are a large number of nuclear encoded genes with estab-
lished or putative mitochondrial functions (>1000 in Mito-
Carta).54 This section could never be exhaustive, and some genes, 
such as AARS2 and DARS2, are discussed elsewhere in detail. 
Many of these disorders are only known to affect children, but 
two disorders of mtDNA maintenance can present with prom-
inent leukoencephalopathy in adulthood, namely mitochon-
drial neurogastrointestinal encephalomyopathy (MNGIE) and 
POLG mutations. MNGIE is an autosomal recessive disorder 
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adulthood with ptosis, chronic progressive external ophthalmo-
plegia, gastrointestinal dysmotility including pseudo-obstruc-
tion, peripheral neuropathy, and diffuse leukoencephalopathy. A 
similar disorder can be caused by mutations in POLG, although 
these cases usually have less prominent leukoencephalopathy.56 
Involvement of the pulvinar of the thalamus has been reported in 
POLG mutations.57 Nuclear encoded mitochondrial gene defects 
can be identified by whole exome or panel sequencing. Variants, 
either single nucleotide variants or deletions, of mtDNA are 
usually identified by specific mtDNA sequencing from affected 
tissue, often muscle.
Leukoencephalopathy with brainstem and spinal cord 
involvement with elevated lactate
Leukoencephalopathy with brainstem and spinal cord involve-
ment with elevated lactate (LBSL) is an unusual and rare leuko-
encephalopathy caused by autosomal recessive mutations in the 
DARS2 gene.58 Usually patients develop symptoms in childhood, 
but the condition tends to be slowly progressive and evolves over 
time, so the diagnosis is usually made when the patient is an adult. 
The most common presentation consists of childhood onset of 
distal weakness and wasting, with pes cavus, and initially patients 
may be given a diagnosis of hereditary sensory motor neurop-
athy. Over time, upper motor neuron signs including spasticity 
and extensor plantar responses develop. Slowly progressive 
ataxia is another common feature, and is due to both cerebellar 
involvement and dorsal column loss. The neuroimaging appear-
ance of LBSL is quite distinct, with a diffuse T2 hyperintense 
signal abnormality of the cerebral and cerebellar white matter, 
corpus callosum, medullary pyramids, medial lemniscus, intra-
parenchymal course of the trigeminal nerves, superior, middle 
and inferior cerebellar peduncles, and the dorsal columns and 
lateral corticospinal tracts of the spinal cord. A lactate peak is 
seen on magnetic resonance spectroscopy, but blood and CSF 
lactate are not elevated59 (figure 2D–F). DARS2 mutations are 
usually compound heterozygous, and the most frequent variant 
is a splice site mutation in intron 2.58 This region is poorly 
covered by next-generation sequencing approaches, and single-
gene testing is recommended if the clinical and radiological 
picture is suggestive of LBSL.
Alexander disease
Caused by heterozygous mutations in GFAP, Alexander disease 
has infantile, juvenile and adult onset forms.60 Mutations 
are often de novo, and young children typically present with 
seizures, motor regression and macrocephaly. GFAP encodes the 
glial fibrillar acidic protein, an essential component of astro-
cytes. Alexander disease is characterised pathologically by the 
presence of Rosenthal fibres, which are long, filamentous eosin-
ophilic fibres largely composed of GFAP protein.61
In infantile cases, death occurs before 2 years. In juvenile 
cases, onset is between 4 and 10 years and is typified by ataxia, 
cognitive decline and bulbar symptoms. Survival can be up to 
20–30 years. Adults tend to present with bulbar or pseudobulbar 
palsy, spasticity, ataxia, cognitive decline and dysautonomia.
The MRI pattern in Alexander disease often falls into two 
extremes. In most infantile and juvenile cases, there is extensive 
white matter abnormality with a frontal predominance. In adults, 
however, the abnormalities are often restricted to the posterior 
fossa, particularly atrophy of the medulla and cervical spinal 
cord. Often the lesions are contrast-enhancing, or there may be 
contrast enhancement of the ventricular lining or periventricular 
rim.62
LMNB1 duplication
Duplication of LMNB1 causes a form of adult-onset, autosomal 
dominant leukodystrophy (ADLD) characterised by autonomic 
dysfunction, spasticity, ataxia and cognitive decline. Symptoms 
usually develop in the fifth or sixth decade.63 Autonomic symp-
toms may be prominent and include orthostatic hypotension, 
urinary incontinence, constipation and erectile dysfunction. 
MRI features include T2W/FLAIR hyperintensity of the subcor-
tical and deep cerebral white matter, the cerebellar peduncles, 
the pyramidal tracts and brainstem.64 It is important to note that 
copy number variants are not reliably identified by next-gen-
eration sequencing. Therefore, if ADLD is suspected clinically, 
specific testing for LMNB1 duplications should be performed.
Hypomyelinating disorders (PLP1, GJC2, TUBB4A, POLR3A, 
POLR3B, CLCN2, NKX6-2)
Hypomyelination is an extremely useful radiological sign, and 
in adults can significantly reduce the number of potential genes 
to test. Hypomyelination should be considered where the T2/
FLAIR hyperintensity is diffuse, and often seems to be affecting 
all of the white matter uniformly. In contrast to demyelinating 
disorders where the white matter signal is hypointense on T1 
imaging, in hypomyelination it may be isointense, or mildly 
hypointense or hyperintense.65 This sign is easily overlooked if 
the T1 sequences are not examined (figure 2G–H).
The most common cause of hypomyelinating leukoenceph-
alopathy is Pelizaeus-Merzbacher disease (PMD), caused by 
mutations in the proteolipid gene PLP1. The most common 
presentations of PMD include the connatal form, where symp-
toms are present at the time of birth, and the classical form, 
where symptoms develop within the first months of life.66 
Symptoms begin with nystagmus, hypotonia, ataxia and head 
tremor. Later motor and language development is delayed. PLP1 
duplications are the most common mutation type in children. 
As PLP1 is an X linked gene, typically male patients are more 
severely affected than female patients. The connatal and classical 
forms are not seen in female patients. However, female PLP1 
mutation carriers can develop symptoms in adulthood. The 
phenotype in women often consists of slowly progressive spastic 
paraplegia and this presentation has been assigned SPG2.67 The 
most common mutation type in female carriers who manifest 
symptoms is a nonsense mutation.68 Adult-onset disease in male 
patients is more aggressive, with prominent head tremor, ataxia, 
spasticity and cognitive decline. MRI in both male and female 
patients shows a diffuse hypomyelinating leukodystrophy which 
is hyperintense on T2/FLAIR and often isointense or mildly 
hyperintense on T1. The pattern can resemble tiger stripes 
(tigroid pattern).
Autosomal recessive mutations in GJC2 are a cause of a Peli-
zaeus-Merzbacher-like disorder.69 The phenotype is similar to 
that of PLP1 mutations but male and female patients are equally 
affected. Like PLP1, most patients have onset of symptoms in 
early life, but there are reports of later onset with slow progres-
sion into adulthood, again mostly manifesting by spastic para-
plegia, cerebellar signs and a hypomyelinating picture on MRI.70
Autosomal recessive mutations in CLCN2 are a very rare 
cause of adult-onset leukoencephalopathy, with findings mainly 
limited to the posterior limb of the internal capsules, the dentate 
nucleus, the cerebral peduncles and middle cerebellar pedun-
cles (figure 2I). There may be evidence of restricted diffusion in 
these areas. There may be more extensive involvement of cere-
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Figure 3 A schematic diagram to illustrate currently available sequencing technologies. Single-gene (Sanger) sequencing is widely available and is 
performed by amplifying coding regions of the gene of interest by PCR, before sequencing these regions. introns and promoter regions are not routinely 
sequenced. Next-generation sequencing-based panel or exome sequencing is becoming more widely available clinically. in this technique, DNA is 
fragmented, and the exons of multiple genes of interest are selected out for sequencing. Although many genes are sequenced, again only the coding 
regions are selected. in whole genome sequencing, which is not routinely available to clinicians yet, the DNA is also fragmented, but all the resulting DNA 
is sequencing, without a selection step. This results in a large amount of data, as the coding regions, intergenic regions, introns and promoters of all human 
genes are sequenced. Advanced bioinformatics and computing technology are a required part of whole genome sequencing.
features of hypomyelination. In adults, the most common 
presentation is mild cerebellar ataxia.71
A number of other genes have been associated with hypomy-
elination, including TUBB4A (with basal ganglia abnormalities),72 
POLR3-related disorders (dental abnormalities and hypogonad-
otrophic hypogonadism)73 and NKX6-2,74 although to date these 
syndromes are only described with childhood onset.
Very rare genes (RNF216, TREM2, SNORD118)
Gordon Holmes syndrome is a rare autosomal recessive disorder 
characterised by hypogonadotrophic hypogonadism and ataxia. 
It is usually accompanied by cognitive decline, diffuse leukoen-
cephalopathy with cerebellar atrophy and chorea. Age of onset 
is variable and the disorder is caused by mutations in the gene 
RNF216. The combination of chorea and dementia is reminis-
cent of an autosomal recessive form of Huntington disease.75
Polycystic lipomembranous osteodysplasia with sclerosing 
leukoencephalopathy, also known as Nasu-Hakola disease, is 
a rare syndrome caused by autosomal recessive mutations in 
TREM2 or TYROBP. The disorder usually presents in adult-
hood, with bone pain and pathological fractures due to bone 
cysts. Later, a severe neuropsychiatric syndrome develops due to 
a progressive leukoencephalopathy. It is most common in Japan 
and Finland.76 Different TREM2 variants are also significant risk 
factors for Alzheimer disease.77
Labrune syndrome, also known as leukoencephalopathy 
with brain calcification and cysts, is a rare autosomal recessive 
disorder caused by mutations in SNORD118. Labrune syndrome 
most commonly presents in early life, but there are reports 
of patients presenting in their 50s. The syndrome consists of 
progressive dementia, with motor decline and seizures. Large 
areas of cystic degeneration and calcification occur with a 
symmetric leukoencephalopathy affecting the periventricular, 
deep and subcortical white matter.78 SNORD118 is not well 
covered by next-generation sequencing, and in the right clinical 
context single-gene sequencing is recommended.
The Queen square Adult Leukodystrophy Group
The Queen Square Adult Leukodystrophy Group (QSALG) 
is a multidisciplinary special interest group with input from 
neuroinflammation, neurogenetics, inherited metabolic disease, 
cognitive neurology and neuroradiology. Since inception, the 
group has investigated 116 patients with a wide variety of white 
matter syndromes, referred from hospitals worldwide. In our 
experience, a diagnosis can be made in approximately half of 
patients (54). The most common diagnoses are found in online 
supplementary figure 1. The most common diagnosis reached 
is of small vessel disease, followed by CSF1R mutations, mito-
chondrial diseases, ALD and multiple sclerosis. The remainder 
of diagnoses were highly heterogeneous, with often only one or 
at most two cases for each disorder. There were 15 diagnoses 
that affected only one patient each, and these included CADASIL 
and CARASIL, PLP1 mutations, Alexander disease and Fabry 
disease, VWM disease and familial British dementia. This review 
is representative of the diagnostic approach of the QSALG.
diagnostic algorithm
Figure 3 shows an algorithm that clinicians can use when eval-
uating adults presenting with a suspected leukoencephalopathy. 
As described above, initial assessment should focus on the exclu-
sion of common acquired causes and severe small vessel disease 
(round 1). If these initial tests are negative and the patient is 
suspected to have a genetic disorder, then the first line of testing 
should include white cell enzyme activities, a VLCFA profile 
(in men), plasma cholestanol and bile alcohols and plasma 
amino acids, to exclude the classical leukodystrophies which 
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Figure 4 A recommended algorithm for the evaluation of adults with suspected inherited white matter disorders. CSF, cerebrospinal fluid; mtDNA, 
mitochondrial DNA; PML, progressive multifocal leukoencephalopathy; vLCFA, very long chain fatty acids; wCe, white cell enzymes.
enzyme replacement therapy and stem cell transplant are being 
explored as treatment options for some of these conditions.
If metabolic testing is not revealing, then the clinician should 
move on to genetic testing in the context of round 3 clinical 
or imaging patterns. A schematic illustrating the differences 
between sequencing approaches can be found in figure 4. 
Next-generation sequencing via diagnostic panels is becoming 
more widely available through regional genetic testing services, 
and these can be the most rapid and cost-effective route to diag-
nosis. It is worth determining which genes are covered by the 
panel requested, as each panel will differ depending on its design. 
If there is no access to a diagnostic panel, then consideration 
should be given to single-gene testing guided by the clinical and 
radiological phenotypes described above, and found in tables 1 
and 2. It should be noted that single-gene testing is a low-yield 
route to diagnosis, and if a number of genes are sequenced the 
cost will quickly exceed that of a diagnostic panel. There are a 
small number of genes where a panel will not be sufficient for 
diagnosis, usually where copy number variants are a significant 
concern, and these would include LMNB1 and PLP1. In these 
cases, clinical suspicion should guide directed testing.
If a panel-based approach is not successful but a genetic leuko-
encephalopathy is still considered likely, then consideration 
should be given to whether the disorder might be due to a muta-
tion in the mitochondrial genome (not targeted by traditional 
panels). It may be necessary to contact a research group who 
can offer more extensive genetic testing including whole exome 
or even whole genome sequencing. In these cases, it is helpful to 
have obtained DNA from as many affected and unaffected family 
members as possible.
In our experience of difficult-to-diagnose patients who have 
already been extensively investigated, a focused exome panel led 
to a diagnosis in almost 30% of patients.3
dIsCussIoN
Leukoencephalopathies are a heterogeneous group of disor-
ders with a wide range of genetic and acquired causes. They are 
frequently difficult to diagnose, and patients with these disorders 
typically undergo a large number of expensive, time-consuming 
and often invasive tests over a long timeframe. This presents a 
significant burden to patients who usually are deteriorating from 
a severe and progressive neurological syndrome. The aim of the 
treating neurologist should be to make a definitive diagnosis, 
as this allows for better prognostication, more definitive family 
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hope that we have given a current useful, straightforward logical 
algorithm that others will find useful. It is clear that careful clin-
ical and radiological assessment, in combination with early use 
of focused genetic testing, is needed to maximise the probability 
of making these diagnoses. However, even with this approach, 
more than half of patients currently do not receive a definitive 
diagnosis.79 This may be because the disorders are so hetero-
geneous or because there are still more genes to be described. 
Advances in genetic technology like whole genome sequencing 
may solve some cases, but only in combination with a thorough 
phenotypic approach.
Ultimately, these diagnoses are important because the develop-
ment of novel therapies for these disorders depends primarily on 
forming cohorts of patients for clinical trials. HSCT from donors 
is a potential treatment for ALD, MLD and a number of other 
disorders. Recently, gene correction has also shown promise. In 
principle, gene correction (eg, through lentiviral transduction 
of the patient’s own cells) should be possible in most loss of 
function genetic disorders, but to show efficacy in rare diseases 
sufficient numbers of patients must be identified.80
As in 2014, the authors are happy to be contacted to discuss 
or see adult-onset patients with possible leukodystrophies or 
genetic leukoencephalopathies.
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